NCT01207492已完成2 期
A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Andrew J. Wagner, MD, PhD7 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2010年9月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 17
- 试验地点
- 7
- 主要终点
- Percentage of Participants With Progression Free Survival
研究概览
简要总结
Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia. Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS). In this research study the investigators are testing whether nilotinib can stop the growth of PVNS or improve the symptoms experienced from PVNS.
详细描述
- In this research study, each cycle of study drug dosing will last 4 weeks (28 days). During each cycle, participants will take nilotinib by mouth twice daily. During the first cycle, participants will come to the clinic on Days 1 and 8. For Cycles 2-4 and every 3 cycles thereafter, they will come to the clinic on Day 1.
- The following tests and procedures will be performed at specific time points during study treatment: MRI or CT scans; physical examinations; vital signs; blood work; questionnaires and EKG.
- Participants may continue in this research study for as long as they do not have serious side effects or their disease does not get worse.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of recurrent PVNS ( or diffuse-type giant cell tumor or tenosynovial giant cell tumor) that is unresectable, metastatic, or for which the patient refuses surgical intervention
- •Progressive disease in the last 12 months, as demonstrated by imaging or clinical appearance of new tumors, in the opinion of the treating investigator
- •At least one site of measurable disease according to RECIST 1.1 on MRI (or CT scan for metastatic disease)
- •Any number or type of prior systemic therapies, with the exception of known or suspected CSF1 receptor inhibitors as outlined in
排除标准
- •18 years of age or older
- •Life expectancy greater than 6 months
- •ECOG Performance Status of 0, 1 or 2
- •Normal organ and marrow function as defined in the protocol
- •QTc less than or equal to 450 ms on 12-lead ECG
- •Negative urine or serum pregnancy test within days of start of study drug administration for women of childbearing potential.
- •Women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 3 months following study drug discontinuation
- •Exclusion Criteria:
- •Prior treatment with known or suspected CSF1 receptor inhibitor, including nilotinib, imatinib, sunitinib, or sorafenib, or other approved or investigational tyrosine kinase inhibitors used for treatment of diffuse-type giant cell tumor
- •Concurrent treatment with other investigational agents
- •Inability to tolerate or contraindication to MRI scanning for participants with localized disease
- •Impaired cardiac function
- •Current treatment with strong CYP3A4 inhibitors that cannot either be discontinued or switched to a different medication prior to starting study drug
- •Current treatment with any medications that have the potential to prolong the QT interval and that cannot either be discontinued or switched to a different medication prior to starting study drug
- •Impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug
- •Acute or chronic pancreatic disease
- •Acute or chronic liver disease
- •Another primary malignant disease requiring systemic treatment or radiation
- •History of significant congenital or acquired bleeding disorder unrelated to cancer
- •Major surgery within 28 days prior to Day 1 of the study
- •Treatment with other investigational agents within 28 days of day 1
- •History of non-compliance to medical regimens or inability to grant consent
- •Women who are pregnant or breastfeeding
- •Other comorbidities that would interfere with study participation or safety in the opinion of the investigator
研究组 & 干预措施
Nilotinib
Experimental
Nilotinib 200 mg taken as 400 mg twice daily, continuously
干预措施: nilotinib (Drug)
结局指标
主要结局
Percentage of Participants With Progression Free Survival
时间窗: 6 months
To estimate progression free survival at 6 months in participants with recurrent PVNS treated with nilotinib. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
次要结局
- Overall Tumor Response Rate (OR)(2 years)
- Clinical Benefit Rate(6 months)
研究者
Andrew J. Wagner, MD, PhD
Sponsor
Dana-Farber Cancer Institute
研究点 (7)
Loading locations...
相似试验
已完成
1 期
Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid TumorsSolid TumorsNCT02379416National Cancer Institute (NCI)47
已完成
2 期
Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaLeukemiaNCT00809211Cancer Trials Ireland40
已完成
1 期
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-LeukemiaChronic Phase Chronic Myeloid LeukemiaAccelerated Phase Chronic Myeloid LeukemiaBlastic Phase Chronic Myeloid LeukemiaPhiladelphia Positive Acute Lymphoblastic LeukemiaResistant to Tyrosine Kinase Inhibitor TherapyNCT01914484University Health Network, Toronto4
尚未招募
2 期
Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell CarcinomaRenal Cell CarcinomaNCT05124431Fudan University30
Unknown
3 期
Nilotinib for First-line Newly Diagnosed CML-CP PatientsChronic Myeloid Leukemia, Chronic PhaseNilotinibNCT03942094Shenzhen Second People's Hospital100